Anna Kan

1.3k total citations · 1 hit paper
38 papers, 927 citations indexed

About

Anna Kan is a scholar working on Hepatology, Molecular Biology and Oncology. According to data from OpenAlex, Anna Kan has authored 38 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 14 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Anna Kan's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Mechanisms and Therapy (9 papers) and Liver Disease Diagnosis and Treatment (8 papers). Anna Kan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Mechanisms and Therapy (9 papers) and Liver Disease Diagnosis and Treatment (8 papers). Anna Kan collaborates with scholars based in China, Canada and Hong Kong. Anna Kan's co-authors include Ming Shi, Rong Guo, Wei Wei, Minke He, QiJiong Li, ZhiCheng Lai, Shaolong Li, Ning Lyu, Qiankun Xie and Ming Zhao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Anna Kan

36 papers receiving 919 citations

Hit Papers

Lenvatinib, toripalimab plus hepatic arterial infusion ch... 2022 2026 2023 2024 2022 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial
    2022 119 citations ZhiCheng Lai, Minke He et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Kan China 16 361 331 275 244 173 38 927
Iris Martinez-Quetglas Spain 5 423 1.2× 331 1.0× 410 1.5× 305 1.3× 253 1.5× 8 1.0k
Yuji Eso Japan 17 382 1.1× 150 0.5× 292 1.1× 168 0.7× 126 0.7× 52 806
Jie Mei China 18 525 1.5× 221 0.7× 263 1.0× 243 1.0× 151 0.9× 51 898
Kornelius Schulze Germany 12 391 1.1× 274 0.8× 295 1.1× 358 1.5× 178 1.0× 23 849
Hanako Tsujikawa Japan 15 466 1.3× 334 1.0× 403 1.5× 262 1.1× 247 1.4× 37 1.2k
Xiaochu Yan China 13 214 0.6× 254 0.8× 289 1.1× 130 0.5× 136 0.8× 33 801
Yi‐Peng Fu China 17 176 0.5× 205 0.6× 389 1.4× 259 1.1× 177 1.0× 32 816
Haosheng Jin China 16 177 0.5× 420 1.3× 294 1.1× 342 1.4× 200 1.2× 52 913
Hironori Kusano Japan 15 228 0.6× 171 0.5× 247 0.9× 137 0.6× 164 0.9× 67 721

Countries citing papers authored by Anna Kan

Since Specialization
Citations

This map shows the geographic impact of Anna Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kan more than expected).

Fields of papers citing papers by Anna Kan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kan. The network helps show where Anna Kan may publish in the future.

Co-authorship network of co-authors of Anna Kan

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Kan. A scholar is included among the top collaborators of Anna Kan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Kan. Anna Kan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kan, Anna, Minke He, Huifang Li, et al.. (2024). Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Frontiers in Immunology. 15. 1260191–1260191. 9 indexed citations
2.
3.
4.
Lai, ZhiCheng, Anna Kan, Hui Liu, et al.. (2024). TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark. 29(7). 243–243.
5.
He, Minke, ZhiCheng Lai, QiJiong Li, et al.. (2023). Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current Opinion in Pharmacology. 70. 102362–102362. 8 indexed citations
6.
Lai, ZhiCheng, JingXian Shen, QiJiong Li, et al.. (2023). Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clinical Cancer Research. 29(24). 5104–5115. 17 indexed citations
7.
Kan, Anna, Shuang Liu, Minke He, et al.. (2023). MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. JHEP Reports. 6(1). 100939–100939. 8 indexed citations
8.
Wen, Dongsheng, et al.. (2023). DNA methylation-activated full-length EMX1 facilitates metastasis through EMX1-EGFR-ERK axis in hepatocellular carcinoma. Cell Death and Disease. 14(11). 769–769. 10 indexed citations
9.
Chen, Dong‐Ping, Shi‐Xun Lu, Jinbin Chen, et al.. (2022). PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. Cancer Research. 82(18). 3307–3320. 12 indexed citations
10.
Lai, ZhiCheng, Minke He, Yu-Jie Xu, et al.. (2022). Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer. 174. 68–77. 119 indexed citations breakdown →
11.
Liu, Shuang, et al.. (2022). Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. Molecular Therapy — Oncolytics. 26. 226–244. 7 indexed citations
12.
13.
Liu, Songyang, et al.. (2021). SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Letters. 528. 16–30. 51 indexed citations
14.
He, Minke, Chuan Peng, Yang Zhao, et al.. (2021). Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology Immunotherapy. 70(11). 3207–3216. 25 indexed citations
15.
Zhao, Yang, Minke He, Dongsheng Wen, et al.. (2021). Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Frontiers in Oncology. 11. 619461–619461. 14 indexed citations
16.
Le, Yong, Anna Kan, QiJiong Li, et al.. (2019). NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. Cancer Cell International. 19(1). 228–228. 23 indexed citations
17.
Zhang, Yong‐Fa, Anna Kan, Xiao-Ping Zhong, et al.. (2019). Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Digestive and Liver Disease. 51(10). 1430–1437. 33 indexed citations
18.
Le, Yong, Jingxian Shen, Yongfa Zhang, et al.. (2019). Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. Journal of Cancer. 10(3). 665–671. 12 indexed citations
19.
Kan, Anna & Rong Guo. (2018). The prognosis of subsequent surgical treatment in patients with sarcomatoid carcinoma in the liver: A retrospective study. International Journal of Surgery. 55. 145–151. 14 indexed citations
20.
Chen, Huadong, et al.. (2014). Intestinal obstruction due to dual gastrointestinal atresia in infants: diagnosis and management of 3 cases. BMC Gastroenterology. 14(1). 108–108. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iris Martinez-Quetglas Breakdown of academic impact, for papers by Yuji Eso Breakdown of academic impact, for papers by Jie Mei Breakdown of academic impact, for papers by Kornelius Schulze Breakdown of academic impact, for papers by Hanako Tsujikawa Breakdown of academic impact, for papers by Xiaochu Yan Breakdown of academic impact, for papers by Yi‐Peng Fu Breakdown of academic impact, for papers by Haosheng Jin Breakdown of academic impact, for papers by Hironori Kusano
Rankless by CCL
2026